Comparative evaluation of screening and supplementary assays used in HCV diagnosis by Nerurkar, Vidya et al.
POSTER PRESENTATION Open Access
Comparative evaluation of screening and
supplementary assays used in HCV diagnosis
Vidya Nerurkar
*, Prabhupad Rath, Rashmi Khadapkar, Simi Bhatia, Bibhu Ranjan Das
From First International Science Symposium on HIV and Infectious Diseases (HIV SCIENCE 2012)
Chennai, India. 20-22 January 2012
Background
Evaluation of serological assays for hepatitis C (HCV)
antibody screening is crucial ,as supplemental testing
[Nucleic Acid Testing & Recombinant Immunoblot
Assay (RIBA)] to verify anti-HCV reactive results is not
widely practiced, due to limited availability and high
cost. The current study was undertaken from January to
May 2011, to evaluate 4 serological assays for HCV
diagnosis, viz-a-viz HCV RNA PCR and RIBA.
Methods
87 patient specimens were screened for anti-HCV, using
COBASe411(eCLIA, Roche, Germany), Axsym (MEIA,
Abbott, Germany), HCV Qualisa (ELISA, Qualpro,
India) and HCV Tridot (Rapid Immunofiltration, J.
Mitra, India), and for presence of HCV RNA using
COBAS TAQMAN 48 analyzer (Roche). Specimens with
discrepant results were referred internationally for RIBA.
Results
58/87 (66.7%) specimens were anti-HCV reactive. 37/58
were HCV RNA PCR positive, indicating active HCV infec-
tion. Sensitivities of COBAS, Axsym, Qualisa and Tridot
were 100%, 97.3%, 72.9% and 75.7% respectively. False
negative anti-HCV results, obtained by Qualisa and Tridot,
were seen in 10 and 9 patients respectively and could be
attributed to the synthetic peptide coating in these kits. 6
of these patients were chronic renal failure cases, on hemo-
dialysis. All kits showed specificity of 100%. False positivity
was not observed, possibly because our study group com-
prised of patients with suspected HCV infection.
Conclusion
Anti-HCV assays on COBASe411 (eCLIA) and Axsym
(MEIA) platforms appear reliable. The study thus
highlights the importance of using recombinant antigen
based tests for anti-HCV screening. A strong need to
conduct larger studies for performance evaluation of
anti-HCV tests in specific patient subpopulations is felt.
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